NME DECEMBER APPROVAL RUSH LIKELY FROM FDA's CARDIO-RENAL AND ANTI-INFECTIVE DIVISIONS, FDA REPORT INDICATES; OF 42 NMEs PENDING AT START OF 1994, 12 APPROVED
A large rush of end-of-the-year NME approvals is likely to issue out of FDA's Divisions of Cardio-Renal Drug Products and Anti-Infective Drug Products based on the number of pending applications at the beginning of 1994 and a lack of new molecular entity approval activity to date in the divisions.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth